← Back to headlines
Eli Lilly Stock Jumps as GLP-1 Sales Expand Novo Lead
Eli Lilly's stock experienced a significant jump following strong GLP-1 sales, further widening its lead over competitor Novo Nordisk.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
